Mundipharma Receives EU Approval for Pelmeg (Pegfilgrastim, Biosimilar)

 Mundipharma Receives EU Approval for Pelmeg (Pegfilgrastim, Biosimilar)

Mundipharma Receives EU Approval for Pelmeg (Pegfilgrastim, Biosimilar)

Shots:

  • Pelmeg (Pegfilgrastim, Biosimilar) is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic CT for malignancy
  • CHMP recommends Pelmeg based on the results from pharmacodynamics, pharmacokinetics, and immunogenicity comparisons with Neulasta
  • Pelmeg is Granulocyte-colony stimulating factor (G-CSF) biosimilar that stimulates bone marrow to produce more neutrophils riginally developed by Cinfa Biotech

Click here to read full press release/ article | Ref: Mundipharma | Image: Wikimedia Commons

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post